fda approval in breast cancer, breakthrough designations in aml and bladder cancer, and more
Published 8 years ago • 284 plays • Length 7:21
Download video MP4
Download video MP3
Similar videos
-
10:18
fda approvals in bladder cancer and hodgkin lymphoma, breakthrough designation in aml, and more
-
9:27
fda approval in bladder cancer, breakthrough therapy designation in dlbcl, and more
-
8:30
fda approvals in bladder cancer, nsclc, aml, hcc, and a breakthrough designation in nsclc
-
8:51
fda approvals in nets, breast cancer, aml, a biosimilar, and more
-
9:29
fda approvals in all and breast cancer, priority reviews in cml and follicular lymphoma, and more
-
7:28
breakthrough designation in all, hifu fda approval, breast cancer screening update, and more
-
10:00
fda approval in breast cancer, review period extended in aml, 2019 aacr highlights, and more
-
9:07
fda approvals in breast cancer and bladder cancer and phase iii data with larotrectinib
-
11:00
fda approval in her2 breast cancer, priority review in nsclc, and more
-
10:46
fda approval in all, priority reviews in cml and breast cancer, and more
-
11:32
fda approvals in breast cancer and nsclc, nda accepted in hcc, and more
-
10:55
fda approval in myeloma, label update in her2 breast cancer, and more
-
7:11
review on 2016 fda approvals, halt on aml trials, and more
-
6:04
breakthrough designation in aml, trials halted in head and neck cancer, and more
-
10:01
fda approvals in sclc and a biosimilar, and japanese approvals in aml, ntrk tumors, and more
-
7:28
fda approvals in pml, nsclc, and breast cancer, priority review in dlbcl, and more
-
9:35
fda approvals in breast cancer and of a biosimilar, nda submitted in cll, and more
-
8:33
pending fda approval of neratinib in her2 breast cancer
-
10:25
fda approvals in gbm, biosimilar in breast cancer and gastric/gej cancer, and biomarker assay
Clip.africa.com - Privacy-policy